http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2010121647-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate | 2008-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2011-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2010121647-A |
| titleOfInvention | C-MET / HGFR INHIBITOR POLYMORPHES |
| abstract | 1. The compound is a salt selected from the group consisting of the hydrochloride salt of 2- [4- (3-quinolin-6-ylmethyl-3H- [1,2,3] triazolo [4,5-b] pyrazin-5 -yl) pyrazol-1-yl] ethanol, the maleate salt of 2- [4- (3-quinolin-6-ylmethyl-3H- [1,2,3] triazolo [4,5-b] pyrazin-5-yl) pyrazol-1-yl] ethanol, phosphate salt of 2- [4- (3-quinolin-6-ylmethyl-3H- [1,2,3] triazolo [4,5-b] pyrazin-5-yl) pyrazol-1 -yl] ethanol, sulfate salt of 2- [4- (3-quinolin-6-ylmethyl-3H- [1,2,3] triazolo [4,5-b] pyrazin-5-yl) pyrazol-1-yl] ethanol and the tosylate salt of 2- [4- (3-quinolin-6-ylmethyl-3H- [1,2,3] triazolo [4,5-b] pyrazin-5-yl) pyrazol-1-yl] ethanol. ! 2. The compound according to claim 1, where the salt is anhydrous. ! 3. The compound according to claim 1, where the salt is a crystalline salt. ! 4. The compound according to claim 1, where the salt is a crystalline anhydrous salt. !5. The compound of claim 1, wherein the salt is a substantially pure polymorph. ! 6. The compound according to claim 1, where the salt is a compound comprising the hydrochloride salt of 2- [4- (3-quinolin-6-ylmethyl-3H- [1,2,3] triazolo [4,5-b] pyrazin-5 -yl) pyrazol-1-yl] ethanol. ! 7. The compound according to claim 1, where the salt is a compound comprising the maleate salt of 2- [4- (3-quinolin-6-ylmethyl-3H- [1,2,3] triazolo [4,5-b] pyrazin-5 -yl) pyrazol-1-yl] ethanol. ! 8. The compound according to claim 1, where the salt is a compound comprising the phosphate salt of 2- [4- (3-quinolin-6-ylmethyl-3H- [1,2,3] triazolo [4,5-b] pyrazin-5 -yl) pyrazol-1-yl] ethanol. ! 9. The compound according to claim 1, where the salt is a compound comprising the sulfate salt of 2- [4- (3-quinolin-6-ylmethyl-3H- [1,2,3] triazolo [4,5-b] pyrazin-5 -yl) pyrazol-1-yl] ethanol. ! 10. The compound according to claim 1, where the salt is a compound comprising the tosylate salt of 2- [4- (3-quinolin-6-ylmethyl-3H- [1,2,3] triazolo [4,5-b] pyrazin-5 -yl) pyrazol-1-yl] ethanol. ! 11. The compound according to claim 3, where the crystalline phosphate salt of 2- [4- (3-quinolin-6-ylmethyl-3H- [1,2,3] triazolo [4,5- |
| priorityDate | 2007-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 14.